- Home
- ENTA vs ZNTL Comparison
ENTA vs ZNTL Comparison
Compare ENTA & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- ZNTL
- Stock Information
- Founded
- ENTA 1995
- ZNTL 2014
- Country
- ENTA United States
- ZNTL United States
- Employees
- ENTA N/A
- ZNTL N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ENTA Health Care
- ZNTL Health Care
- Exchange
- ENTA Nasdaq
- ZNTL Nasdaq
- Market Cap
- ENTA 245.4M
- ZNTL 273.1M
- IPO Year
- ENTA 2013
- ZNTL 2020
- Fundamental
- Price
- ENTA $9.31
- ZNTL $3.17
- Analyst Decision
- ENTA Buy
- ZNTL Buy
- Analyst Count
- ENTA 3
- ZNTL 8
- Target Price
- ENTA $19.67
- ZNTL $10.50
- AVG Volume (30 Days)
- ENTA 114.1K
- ZNTL 1.6M
- Earning Date
- ENTA 11-25-2024
- ZNTL 11-12-2024
- Dividend Yield
- ENTA N/A
- ZNTL N/A
- EPS Growth
- ENTA N/A
- ZNTL N/A
- EPS
- ENTA N/A
- ZNTL N/A
- Revenue
- ENTA $71,960,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- ENTA N/A
- ZNTL N/A
- Revenue Next Year
- ENTA $5.14
- ZNTL N/A
- P/E Ratio
- ENTA N/A
- ZNTL N/A
- Revenue Growth
- ENTA N/A
- ZNTL N/A
- 52 Week Low
- ENTA $8.51
- ZNTL $2.66
- 52 Week High
- ENTA $17.80
- ZNTL $18.07
- Technical
- Relative Strength Index (RSI)
- ENTA 28.86
- ZNTL 42.66
- Support Level
- ENTA $10.84
- ZNTL $2.90
- Resistance Level
- ENTA $10.89
- ZNTL $3.20
- Average True Range (ATR)
- ENTA 0.49
- ZNTL 0.40
- MACD
- ENTA -0.19
- ZNTL -0.08
- Stochastic Oscillator
- ENTA 18.18
- ZNTL 10.39
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.